All you need to get started with ETF selection and analysis. Create your account now →

Help us improve your experience. Please confirm your investor type:

ETF What's Up

Don’t Miss a Move in the ETF Market

Sign up and keep track of everything that moved the ETF industry this week. From new launches to regulatory shifts across the Atlantic.

ETF What's Up

You may unsubscribe at any time by clicking the “unsubscribe” link within the emailed newsletter. By signing up, you agree to our Privacy Policy and Terms and Conditions.

ETF IssuersGlobal X09820
09820

Global X China Biotech ETF

The 09820 Exchange Traded Fund (ETF) is provided by Global X. It is built to track an index: Solactive China Biotech Index. The 09820 ETF provides physical exposure, so by buying it you actually own parts of all the 31 underlying holdings. This share class generates a stream of income by distributing dividends.

Advertisement

Advertisement

-
N/A
N/A
1D price range
N/A
52W price range
YTD Perf.
-
YTD Flows
Annualized volatility
Fund AuM
€0
Share class AuM
€0
TTM Yield
Tracking Error
Tracking Difference
ISIN
HK0000516697HK0000516689
TER
0.68%
Inception date
7/25/2019
Issuer
Replication method
Dividend policy
Compare similar ETFs
API
Performance
0%
Flows
Join for free to unlock
Data as of 06/30/26
Healthcare
94.68%
Unavailable
5.31%
Latest 09820 news

No content available for this fund

FAQ about 09820

09820 is a Passive ETF. This ETF provides exposure to Chinese Biotechnology Equities.
09820 tracks the Solactive China Biotech Index - CNY, through a full replication replication method.
09820 carries a total expense ratio (TER) of 0.68%, indicating the annual cost for holding the fund.
09820 was introduced to the market on July 25, 2019. It trades on Hong Kong
Global X China Biotech ETF, 09820, is provided by Global X. Learn more about Global X here.
09820 follows a distributing dividend policy, meaning it pays out income to investors.
As of June 30, 2026, 09820 has significant geographic allocations in China, Switzerland and Hong Kong.
As of June 30, 2026, 09820 focuses largely on Healthcare.
As of June 30, 2026, 09820 holds 31 positions in its portfolio, with 78.59% of assets concentrated in its top 15 holdings.
As of June 30, 2026, 09820 top three holdings include WuXi AppTec Co., Ltd., WuXi Biologics (Cayman), Inc. and BeOne Medicines Ltd..
The base currency of 09820 is CNY.
Data as of 06/30/26
WuXi AppTec Co., Ltd.
13.16%
WuXi Biologics (Cayman), Inc.
9.59%
BeOne Medicines Ltd.
9.08%
Innovent Biologics, Inc.
8.91%
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
8.52%
Akeso, Inc.
5.63%
Sino Biopharmaceutical Ltd.
4.04%
Hansoh Pharmaceutical Group Co., Ltd.
3.36%
3SBio, Inc.
3.06%
Shanghai Allist Pharmaceuticals Co., Ltd.
2.66%

Trackinsight
Essentials

A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.

Essential free account includes:
  • More fund data
  • Compare up to 3 funds
  • More screener filters
  • Edit screener columns from 100+ metrics
  • Watchlists for saving your research
  • Portfolio construction and analysis
  • Personal dashboard for live monitoring

Advertisement

Trackinsight

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight
© 2014-2026 Trackinsight SA. All rights reserved.
Privacy policy  |  Cookie policy  |    |  Terms of use  |  Imprint
Trackinsight